News & Videos - MYLAN N.V. - Page 5

Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets Erlotinib Hydrochloride Tablets treat metastatic non-small cell lung and pancreatic cancers PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, May 10, 2019 HERTFORDSHIRE, England , and PITTSBURGH , May 10, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg, a generic version of Genentech's Tarceva ® ....

Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 10, 2019 HERTFORDSHIRE, England and PITTSBURGH , May 10, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the 2019 Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Thursday, May 16, 2019 at 10:40 a.m. PT / 1:40 p.m. ET . Interested parties can access a live...

Mylan Reports First Quarter 2019 Results and Reaffirms 2019 Guidance PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 7, 2019 HERTFORDSHIRE, England and PITTSBURGH , May 7, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three months ended March 31, 2019. First Quarter 2019 Financial Highlights U.S. GAAP diluted loss per ordinary share ("U.S. GAAP EPS") of $(0.05) as compared to earnings of $0.17 per ordinary share in the prior year period. Total...

Mylan to Release First Quarter 2019 Financial Results on May 7, 2019 PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, April 26, 2019 HERTFORDSHIRE, England , and PITTSBURGH , April 26, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its first quarter 2019 financial results on Tues., May 7 , before the open of the U.S. financial markets. The company also will host a webcast at 10 a.m. ET on May 7 , to discuss the results. The...

TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB) TB is a global epidemic responsible for 1.6 million deaths in 2017(1) Regimens under clinical development include treatment options for drug-resistant forms of TB PR Newswire NEW YORK and HERTFORDSHIRE, England and PITTSBURGH, April 18, 2019 NEW YORK and HERTFORDSHIRE, England and PITTSBURGH , April 18, 2019 /PRNewswire/ -- Non-profit drug...

Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available PR Newswire HERTFORDSHIRE, England and PITTSBURGH, April 3, 2019 HERTFORDSHIRE, England and PITTSBURGH , April 3, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ:MYL) is committed to doing its part to achieve a positive, sustained impact on the world around us, from ensuring responsible operations that provide high quality medicine in more than 165...

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter PR Newswire ROCKFORD, Ill., March 18, 2019 ROCKFORD, Ill. , March 18, 2019 /PRNewswire/ -- Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL tothe consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC. The...

SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation Money to Aid Ongoing Recovery Efforts in Puerto Rico, Funding the Rebuild and Repair of at Least 100 Homes PR Newswire HERTFORDSHIRE, England and PITTSBURGH and SAN JUAN, Puerto Rico, March 7, 2019 HERTFORDSHIRE, England and PITTSBURGH and SAN JUAN, Puerto Rico , March 7, 2019 /PRNewswire/ -- A small crowd of SBP staff, AmeriCorps members, Puerto Rico Central...

Mylan to Present at Raymond James 40th Annual Institutional Investors Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 28, 2019 HERTFORDSHIRE, England and PITTSBURGH , Feb. 28, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CFO Ken Parks will present at the Raymond James 40th Annual Institutional Investors Conference in Orlando, Fla. , on Tuesday, March 5, 2019 , at 7:30 a.m. ET . Interested parties can access a live webcast of...

Mylan Reports Fourth Quarter and Full Year 2018 Results and Provides 2019 Guidance PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 26, 2019 HERTFORDSHIRE, England and PITTSBURGH , Feb. 26, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the fourth quarter and the year ended December 31, 2018 and provided 2019 guidance. Fourth Quarter 2018 Financial Highlights Total revenues of $3.08 billion , down 5% compared to the prior year period Rest of World...

Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2019 HERTFORDSHIRE, England and PITTSBURGH , Feb. 22, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, a generic version of Indivior's Suboxone® Sublingual Film. Mylan Pharmaceuticals received final approval from the U.S. Food and...

Mylan Launches Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand Unique Pricing of Wixela Inhub Immediately Benefits Patients and Reduces Overall Cost to the U.S. Healthcare System PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 12, 2019 HERTFORDSHIRE, England and PITTSBURGH , Feb. 12, 2019 /PRNewswire/ -- Mylan N.V....

Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019 PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Feb. 11, 2019 HERTFORDSHIRE, England , and PITTSBURGH , Feb. 11, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2018 financial results, as well as its 2019 financial guidance, on Tuesday, Feb. 26 , after the close of the U.S. financial markets. The...

Mylan Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) Wixela™ Inhub™ is the first FDA-approved therapeutically equivalent generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or chronic obstructive pulmonary disease (COPD) As a therapeutic equivalent, Wixela Inhub can be...

Mylan to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 20, 2018 HERTFORDSHIRE, England and PITTSBURGH , Dec. 20, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. , on Tuesday, Jan. 8, 2019 , at 11 a.m. PT / 2 p.m. ET . Interested parties can access a live webcast of the...

Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering Mesalamine Delayed-Release Tablets help individuals manage their ulcerative colitis. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 17, 2018 HERTFORDSHIRE, England and PITTSBURGH , Dec. 17, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Mesalamine Delayed-Release Tablets USP, 1.2 g, a generic version of Shire's Lialda®...

Mylan Adds First Generic for Canasa® Rectal Suppository to Growing Gastroenterology Portfolio Mylan's Mesalamine Rectal Suppository treats mildly to moderately active ulcerative proctitis The company is awarded 180 days of marketing exclusivity PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 17, 2018 HERTFORDSHIRE, England and PITTSBURGH , Dec. 17, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Mesalamine Rectal...

Mylan Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to All Lots Within Expiry Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2018 HERTFORDSHIRE, England and PITTSBURGH , Dec. 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its...

Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets Mylan's Lansoprazole Delayed-Release Orally Disintegrating Tablets are approved to treat certain types of gastrointestinal ulcers PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2018 HERTFORDSHIRE, England and PITTSBURGH , Dec. 4, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Lansoprazole...

Mylan to Present at Nasdaq's 39th London Investor Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 26, 2018 HERTFORDSHIRE, England and PITTSBURGH , Nov. 26, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will present at Nasdaq's 39 th London Investor Conference on Tuesday, Dec. 4, 2018 , at 9:45 a.m. GMT / 4:45 a.m. ET . Interested parties can access a live webcast of the presentation via the investor relations section of...